Navigation Links
IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
Date:6/30/2010

GAITHERSBURG, Md., June 30 /PRNewswire-USNewswire/ -- In recognition of its leadership in the optimization, validation and routine use of non-animal testing methods, The Institute for In Vitro Sciences (IIVS), Inc. has been awarded the first Mark Twain Ethical Science Award. This honor, presented by People for the Ethical Treatment of Animals (PETA), recognizes IIVS for its successes in helping hundreds of companies world-wide utilize testing strategies that minimize the use of animals, while at the same time maintain or improve the current level of safety for the public.

IIVS is a non-profit organization operating as a center of excellence for in vitro (non-animal) methods used for product safety testing purposes. IIVS's knowledge of the science and application of alternatives to animal experiments is recognized by regulatory agencies worldwide. It provides education and training for chemical and personal care product companies internationally, enabling them to successfully apply non-animal methods within their product testing programs. IIVS also performs testing services in their own quality controlled laboratories providing access to their expert scientific team on a contract basis.

"We are honored to be the first recipient of this prestigious award from PETA", said Dr Rodger Curren, President of IIVS. "Their continued support of our work to expand the application of non-animal methods for product testing has been extremely critical for many of our successes". As an example, Curren pointed out that PETA had recently provided partial funding for IIVS to participate in an international study for non-animal methods to detect skin irritants which resulted in the European Union accepting certain reconstructed human skin models for regulatory submissions. Curren added that an increasing number of scientists have found that the use of human artificial tissue constructs for product safety testing can provide much more accurate assessments of the potential risk to humans than testing in animals.

IIVS has worked for over thirteen years to advance the field of in vitro alternatives. The Mark Twain Ethical Science Award provides a clear demonstration of the impact of its work.

About IIVS

IIVS is a non-profit organization wholly dedicated to the promotion of rapid and innovative non-animal testing methods. Founded in 1997, IIVS is recognized as a leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programs coupled with educational and outreach initiatives have established IIVS as a global leader in the advancement of alternatives to animal testing.

For more information please visit www.iivs.org


'/>"/>
SOURCE Institute for In Vitro Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... to sell research and genetic testing lab equipment from two different leading institutes. This ... and Northeast regions of the United States. This 1-day online auction will take ...
(Date:1/18/2017)... Texas , Jan. 18, 2017  Caris ... and the Lustgarten Foundation, the largest private funder ... a clinical trial evaluating the impact of immunotherapy ... providing clinical trial enrollment services to identify potential ... facilitate communication between treating physicians and study investigators. ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
Breaking Biology News(10 mins):